ClinicalTrials.gg
Not yet recruitingNCT07840833Updated Sep 25, 2026

Prevalence of Helicobacter Pylori Infection

An observational study in Residents of Palau Aged 18 Years or Older, sponsored by Fu Jen Catholic University Hospital. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Fu Jen Catholic University Hospital · Observational

Updated Sep 25, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

  1. To investigate the prevalence of Helicobacter pylori infection among adults in Palau using stool antigen testing.
  2. To analyze the correlation between H. pylori infection and demographic variables (e.g., age, gender, lifestyle).
  3. To provide data for future screening and eradication programs to reduce the incidence of gastric cancer locally.
Read the detailed description

Helicobacter pylori is a Gram-negative spiral-shaped bacterium that is a major cause of chronic gastritis, gastric ulcers, and duodenal ulcers. It is also a significant pathogenic factor in gastric cancer. According to the World Health Organization (WHO), H. pylori is classified as a Group 1 carcinogen. A community-based screening and eradication program in Matsu, Taiwan has shown that active screening and eradication of H. pylori effectively reduced the incidence and mortality of gastric cancer. Currently, there is a lack of basic epidemiological data on the prevalence of H. pylori infection in Palau. This study aims to investigate the prevalence among adults in Palau to provide a reference for future public health intervention strategies.

Studies on H. pylori prevalence in Pacific Island nations have shown varying infection rates. For example, the prevalence among adults has been reported at around 60-70% in some regions, such as Papua New Guinea and the Solomon Islands, with lower rates observed in urbanized areas of Fiji and higher rates in rural communities. These findings emphasize the importance of regional data collection to inform targeted public health responses.

02

Conditions studied

  • Residents of Palau Aged 18 Years or Older

Browse trials for

Keywords

  • Helicobacter pylori
  • Gastric cancer
  • Prevalence
  • Palau
03

In context

Stomach Neoplasms

3,399 studies on the registry are indexed under Stomach Neoplasms; 992 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 278 across 790 observational studies indexed under Stomach Neoplasms.

Browse Stomach Neoplasms studies →

Lead sponsor

Fu Jen Catholic University Hospital is the lead sponsor of 33 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Residents of Palau

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Residents of Palau aged 18 years or older

Exclusion criteria

Exclusion Criteria:

  • Individuals who have used antibiotics within the past 4 weeks or proton pump inhibitors within the past 2 weeks
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Residents of Palau

    aged 18 years or older

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Helicobacter Pylori Infection

    To investigate the prevalence of Helicobacter pylori infection among adults in Palau using stool antigen testing

    Time frame: 3 Months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07840833
Lead sponsor
Fu Jen Catholic University Hospital
Responsible party
Meg Chuang (Gastroenterology and Hepatology, Fu Jen Catholic University Hospital) — Principal investigator
First posted
Sep 25, 2026
Start date
Aug 27, 2026 (estimated)
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Fu-Jen Lee
Contact
paul6130@gmail.com
886-905301873

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion